Mertins Tamara, Nilius Henning, Boss Robin, Knuchel Matthias, Signorell Andri, Huber Carola A, Blozik Eva, Kremer Hovinga Johanna Anna, Bachmann Lucas M, Nagler Michael
Department of Clinical Chemistry, Inselspital, Bern University Hospital, Bern, Switzerland.
Department of Health Sciences, Helsana Group, Zurich, Switzerland.
Front Cardiovasc Med. 2022 Aug 3;9:963528. doi: 10.3389/fcvm.2022.963528. eCollection 2022.
Prevention of recurrent venous thromboembolism (VTE) is considered a main goal of VTE management. However, the extent to which physicians adhere to the recommendations from evidence-based guidelines is unknown.
From a large, prospective clinical cohort, we aimed to (1) quantify the adherence of treatment recommendations to evidence-based guidelines and establish its predictors, and (2) estimate its impact on clinical outcomes and costs in patients with VTE.
We included 6'243 consecutive patients with VTE treated at the university outpatient unit. Detailed clinical characteristics and treatment recommendations were recorded. Adherence of treatment recommendations to evidence-based guidelines was assessed in terms of duration of anticoagulant treatment. Data on death were obtained from the Swiss Central Compensation Office. Health care claims data recorded between 2014 and 2019 were retrieved from Helsana, one of the largest Swiss health insurance companies.
The adherence to evidence-based guidelines was 36.1%. Among patients with non-adherence, overtreatment was present in 70.1%. Significant patient-related predictors of guideline adherence were (a) age above 50 years, (b) male sex, (c) pulmonary embolism, (d) unprovoked VTE, (e) multiple VTE, (f) laboratory tests not ordered, and (g) various cardiovascular comorbidities. Non-adherence was not significantly associated with mortality, hospitalization, admission to nursing home, and costs.
The adherence to evidence-based guidelines was low, and several unrelated predictors appeared. Although these results need to be confirmed in other settings, they highlight the need for implementation of evidence-based guidelines in clinical practice.
预防复发性静脉血栓栓塞症(VTE)被视为VTE管理的主要目标。然而,医生对循证指南建议的遵循程度尚不清楚。
基于一个大型前瞻性临床队列,我们旨在(1)量化治疗建议对循证指南的遵循情况并确定其预测因素,以及(2)评估其对VTE患者临床结局和成本的影响。
我们纳入了在大学门诊接受治疗的6243例连续的VTE患者。记录详细的临床特征和治疗建议。根据抗凝治疗时长评估治疗建议对循证指南的遵循情况。死亡数据来自瑞士中央赔偿办公室。2014年至2019年期间记录的医疗保健理赔数据从瑞士最大的健康保险公司之一赫尔萨纳(Helsana)获取。
对循证指南的遵循率为36.1%。在未遵循的患者中,70.1%存在过度治疗。与指南遵循情况显著相关的患者因素包括:(a)年龄超过50岁,(b)男性,(c)肺栓塞,(d)特发性VTE,(e)多次VTE,(f)未进行实验室检查,以及(g)各种心血管合并症。未遵循与死亡率、住院率、入住养老院率及成本无显著关联。
对循证指南的遵循率较低,且出现了一些不相关的预测因素。尽管这些结果需要在其他环境中得到证实,但它们凸显了在临床实践中实施循证指南的必要性。